BioSante Pharmaceuticals, Inc. (BPAX)

[nutsyprofessor]

Well, like I've been saying all along, aside from the cancer vaccine portfolio which has a longer timeframe to develop and therefore harder to value at this time; the big player here is still LibiGel. Yes, I know that T-gel is about to have an FDA decision and an approval is a huge plus but not necessarily because of it's revenue value but more so because it would represent multiple gel product approvals for BioSante which bodes well for LibiGel down the road. June is a VERY important month for LibiGel...keep your eye on news from BPAX around that timeframe.

My prediction: LibiGel will be the Pheonix that rises from the fire!